{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:16:08Z","timestamp":1792602968145,"version":"4.5.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["B16046"],"award-info":[{"award-number":["B16046"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M652030"],"award-info":[{"award-number":["2019M652030"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.apsb.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T21:53:39Z","timestamp":1590184419000},"page":"30-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Selective inhibition of CDK4\/6: A safe and effective strategy for developing anticancer drugs"],"prefix":"10.1016","volume":"11","author":[{"given":"Kai","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-941X","authenticated-orcid":false,"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.05.001_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.05.001_bib2","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.05.001_bib3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/2594","article-title":"Understanding the cell cycle","volume":"4","author":"Nurse","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.05.001_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1020918107706","article-title":"Yeast and cancer","volume":"22","author":"Hartwell","year":"2002","journal-title":"Biosci Rep"},{"key":"10.1016\/j.apsb.2020.05.001_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1023\/A:1022017701871","article-title":"Cyclin dependent kinases and cell cycle control","volume":"22","author":"Nurse","year":"2002","journal-title":"Biosci Rep"},{"key":"10.1016\/j.apsb.2020.05.001_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","article-title":"Inhibitors of cyclin-dependent kinases as cancer therapeutics","volume":"173","author":"Whittaker","year":"2017","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.apsb.2020.05.001_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-017-4385-3","article-title":"Cyclin-dependent kinase 4\/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib","volume":"166","author":"Kwapisz","year":"2017","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.apsb.2020.05.001_bib10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1006\/jmbi.1999.2640","article-title":"Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors","volume":"287","author":"Pavletich","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/cbt.72","article-title":"Cycling to cancer with cyclin D1","volume":"1","author":"Diehl","year":"2002","journal-title":"Canc Biol Ther"},{"key":"10.1016\/j.apsb.2020.05.001_bib12","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cdks, cyclins and CKIs: roles beyond cell cycle regulation","volume":"140","author":"Lim","year":"2013","journal-title":"Development"},{"key":"10.1016\/j.apsb.2020.05.001_bib13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0092-8674(91)90101-4","article-title":"Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle","volume":"65","author":"Matsushime","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.05.001_bib14","doi-asserted-by":"crossref","first-page":"7114","DOI":"10.1038\/sj.onc.1208853","article-title":"Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins","volume":"24","author":"Yu","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2020.05.001_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1101\/gad.7.3.331","article-title":"Direct binding of cyclin-D to the retinoblastoma gene-product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4","volume":"7","author":"Kato","year":"1993","journal-title":"Gene Dev"},{"key":"10.1016\/j.apsb.2020.05.001_bib16","first-page":"2066","article-title":"D-type cyclin-dependent kinase-activity in mammalian-cells","volume":"14","author":"Matsushime","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0959-437X(95)90057-8","article-title":"The retinoblastoma tumor suppressor protein","volume":"5","author":"Hinds","year":"1995","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.apsb.2020.05.001_bib18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc2399","article-title":"Cellular mechanisms of tumour suppression by the retinoblastoma gene","volume":"8","author":"Burkhart","year":"2008","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.apsb.2020.05.001_bib19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/MCB.18.2.753","article-title":"Functional inactivation of the retinoblastoma protein requires sequential modification by at least two\u00a0distinct cyclin\u2013cdk complexes","volume":"18","author":"Lundberg","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(00)81519-6","article-title":"Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1","volume":"98","author":"Harbour","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.05.001_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","article-title":"The strange case of CDK4\/6 inhibitors: mechanisms, resistance, and combination strategies","volume":"3","author":"Knudsen","year":"2017","journal-title":"Trends Canc"},{"key":"10.1016\/j.apsb.2020.05.001_bib22","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Gene Dev"},{"key":"10.1016\/j.apsb.2020.05.001_bib23","first-page":"73","article-title":"Cyclin D-dependent kinases, INK4 inhibitors and cancer","volume":"1602","author":"Ortega","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2020.05.001_bib24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/366704a0","article-title":"A new regulatory motif in cell-cycle control causing specific-inhibition of cyclin-D\/CDK4","volume":"366","author":"Serrano","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.05.001_bib25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic Ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.05.001_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(94)90573-8","article-title":"P27, a novel inhibitor of G1 cyclin-Cdk protein-kinase activity, is related to p21","volume":"78","author":"Toyoshima","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.05.001_bib27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1101\/gad.9.6.650","article-title":"p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor-suppressor gene","volume":"9","author":"Matsuoka","year":"1995","journal-title":"Gene Dev"},{"key":"10.1016\/j.apsb.2020.05.001_bib28","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1158\/0008-5472.CAN-05-2203","article-title":"Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3","volume":"66","author":"Kenneth","year":"2006","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib29","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1242\/jcs.039131","article-title":"Transcriptional regulation of the cyclin D1 gene at a glance","volume":"121","author":"Klein","year":"2008","journal-title":"J Cell Sci"},{"key":"10.1016\/j.apsb.2020.05.001_bib30","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cub.2006.04.044","article-title":"Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression","volume":"16","author":"Yamamoto","year":"2006","journal-title":"Curr Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2020.05.001_bib32","first-page":"1812","article-title":"Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining","volume":"54","author":"Gillett","year":"1994","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2005.12.012","article-title":"Requirement for CDK4 kinase function in breast cancer","volume":"9","author":"Yu","year":"2006","journal-title":"Canc Cell"},{"key":"10.1016\/j.apsb.2020.05.001_bib34","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-08-3185","article-title":"Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas","volume":"15","author":"Italiano","year":"2009","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1078-0432.CCR-13-1645","article-title":"LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma","volume":"20","author":"Yoshifumi","year":"2014","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib36","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.4161\/cc.10.15.16776","article-title":"The meaning of p16ink4a expression in tumors: functional significance, clinical associations and future developments","volume":"10","author":"Witkiewicz","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.apsb.2020.05.001_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1541-7786.MCR-13-0350","article-title":"The molecular balancing act of p16INK4a in cancer and aging","volume":"12","author":"LaPak","year":"2014","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib38","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.05.001_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mrfmmm.2004.08.021","article-title":"INK4a\/ARF: a multifunctional tumor suppressor locus","volume":"576","author":"Sharpless","year":"2005","journal-title":"Mutat Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fonc.2018.00303","article-title":"Targeting cyclin-dependent kinases for treatment of gynecologic cancers","volume":"8","author":"Lin","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0002-9378(13)70310-7","article-title":"The p53 tumor suppressor gene frequently is altered in gynecologic cancers","volume":"170","author":"Berchuck","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.apsb.2020.05.001_bib42","first-page":"5171","article-title":"Frequent allelic losses and mutations of the p53 gene in human ovarian cancer","volume":"51","author":"Okamoto","year":"1991","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib43","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1101\/gad.181933.111","article-title":"The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression","volume":"26","author":"Sadasivam","year":"2012","journal-title":"Gene Dev"},{"key":"10.1016\/j.apsb.2020.05.001_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1083\/jcb.200909144","article-title":"Activation of cyclin B1\u2013Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis","volume":"189","author":"Gavet","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nature06046","article-title":"Cdk1 is sufficient to drive the mammalian cell cycle","volume":"448","author":"Santamaria","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.05.001_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","article-title":"Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1","volume":"2","author":"Aarts","year":"2012","journal-title":"Canc Discov"},{"key":"10.1016\/j.apsb.2020.05.001_bib47","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1101\/gad.8.15.1772","article-title":"Differential regulation of E2F transactivation by cyclin\/cdk2 complexes","volume":"8","author":"Dynlacht","year":"1994","journal-title":"Gene Dev"},{"key":"10.1016\/j.apsb.2020.05.001_bib48","doi-asserted-by":"crossref","first-page":"35728","DOI":"10.1074\/jbc.M110.154005","article-title":"Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK\u00b7cyclin complexes","volume":"285","author":"Marais","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/cdd.2009.221","article-title":"Cyclin-C-dependent cell-cycle entry is required for activation of non-homologous end joining DNA repair in postmitotic neurons","volume":"17","author":"Tomashevski","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.apsb.2020.05.001_bib50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2011.04.115","article-title":"Phosphorylation of human DNMT1: implication of cyclin-dependent kinases","volume":"409","author":"Lavoie","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2020.05.001_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/374283a0","article-title":"Cdk-activating kinase complex is a component of human transcription factor TFIIH","volume":"374","author":"Shiekhattar","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.05.001_bib52","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1091\/mbc.e04-11-0982","article-title":"Impairment of the TFIIH-associated CDK-activating kinase selectively affects cell cycle-regulated gene expression in fission yeast","volume":"16","author":"Lee","year":"2005","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.apsb.2020.05.001_bib53","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/embor.2010.153","article-title":"Cyclin-dependent kinase 9\u2013cyclin K functions in the replication stress response","volume":"11","author":"Yu","year":"2010","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2020.05.001_bib54","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1101\/gad.1968210","article-title":"CDK12 is a transcription elongation-associated CTD kinase,\u00a0the metazoan ortholog of yeast Ctk1","volume":"24","author":"Bartkowiak","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.apsb.2020.05.001_bib55","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature07179","article-title":"CDK8 is a colorectal cancer oncogene that regulates \u03b2-catenin activity","volume":"455","author":"Firestein","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.05.001_bib56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrm1467","article-title":"Cell signalling and the control of pre-mRNA splicing","volume":"5","author":"Shin","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib57","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1074\/jbc.M708188200","article-title":"Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection","volume":"283","author":"Loyer","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib58","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1016\/j.bmcl.2015.05.100","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs","volume":"25","author":"S\u00e1nchez-Mart\u00ednez","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib59","first-page":"1143","article-title":"Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy","volume":"9","author":"Sedlacek","year":"1996","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib60","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib61","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543784.2013.789859","article-title":"Cyclin-dependent kinase inhibitor therapy for hematologic malignancies","volume":"22","author":"Bose","year":"2013","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.apsb.2020.05.001_bib62","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada clinical trials group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib63","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/01.COT.0000450374.31680.1d","article-title":"Orphan drug status for alvocidib","volume":"36","author":"Times","year":"2014","journal-title":"Oncol Times"},{"key":"10.1016\/j.apsb.2020.05.001_bib65","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.10738","article-title":"In\u00a0vitro and in\u00a0vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)","volume":"102","author":"Mcclue","year":"2002","journal-title":"Int J Canc"},{"key":"10.1016\/j.apsb.2020.05.001_bib66","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","article-title":"Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies","volume":"46","author":"Le Tourneau","year":"2010","journal-title":"Eur J Canc"},{"key":"10.1016\/j.apsb.2020.05.001_bib67","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"11","author":"Nemunaitis","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2020.05.001_bib69","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.V116.21.3287.3287","article-title":"Phase II study of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced acute leukemias","volume":"116","author":"Gojo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2020.05.001_bib70","first-page":"169","article-title":"Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer","volume":"14","author":"Mita","year":"2014","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.apsb.2020.05.001_bib71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2013.11.020","article-title":"Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer","volume":"83","author":"Stephenson","year":"2014","journal-title":"Lung Canc"},{"key":"10.1016\/j.apsb.2020.05.001_bib72","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2016-10-748210","article-title":"Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"129","author":"Ghia","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2020.05.001_bib73","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/1535-7163.MCT-12-0286","article-title":"BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application","volume":"11","author":"Gerhard","year":"2012","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib74","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jtho.2019.01.010","article-title":"Phase II study of roniciclib in combination with cisplatin\/etoposide or carboplatin\/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer","volume":"14","author":"Reck","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib75","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/1535-7163.MCT-06-0613","article-title":"In\u00a0vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00","volume":"6","author":"Joshi","year":"2007","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib76","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/leu.2008.378","article-title":"Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma","volume":"23","author":"Raje","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2020.05.001_bib77","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clml.2015.02.021","article-title":"A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"15","author":"Cassaday","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.apsb.2020.05.001_bib78","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-08-0836","article-title":"AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts","volume":"8","author":"Byth","year":"2009","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib79","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00280-006-0371-x","article-title":"A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers","volume":"60","author":"Camidge","year":"2007","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.apsb.2020.05.001_bib80","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/annonc\/mdp377","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours","volume":"21","author":"Boss","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib81","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib82","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in\u00a0vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib83","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.apsb.2020.05.001_bib84","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the carolina breast cancer study","volume":"295","author":"Carey","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.apsb.2020.05.001_bib85","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.critrevonc.2017.02.022","article-title":"CDK4\/6 inhibitors in HER2-positive breast cancer","volume":"112","author":"Corona","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.apsb.2020.05.001_bib86","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.05.001_bib87","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib88","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","article-title":"Palbociclib: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2020.05.001_bib89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.008","article-title":"CDK4\/6 inhibitors in breast cancer therapy: current practice and future opportunities","volume":"191","author":"Lynce","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2020.05.001_bib90","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/jm000271k","article-title":"Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases","volume":"43","author":"Barvian","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib91","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib92","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/jm049355+","article-title":"Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4","volume":"48","author":"Vanderwel","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib93","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib94","doi-asserted-by":"crossref","first-page":"9105","DOI":"10.1021\/acs.jmedchem.8b00049","article-title":"How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases?.","volume":"61","author":"Jorda","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib95","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1021\/jm0600388","article-title":"Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition","volume":"49","author":"Lu","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib96","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib97","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991\u00a0in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib98","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2020.05.001_bib99","author":"Li","year":"2014"},{"key":"10.1016\/j.apsb.2020.05.001_bib100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-017-1231-7","article-title":"CDK4\/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest","volume":"15","author":"Wang","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2020.05.001_bib101","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/cas.13957","article-title":"Preclinical characterization of SHR6390, a novel CDK 4\/6 inhibitor, in\u00a0vitro and in human tumor xenograft models","volume":"110","author":"Long","year":"2019","journal-title":"Canc Sci"},{"key":"10.1016\/j.apsb.2020.05.001_bib102","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejmech.2016.07.020","article-title":"New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities","volume":"122","author":"Wang","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib103","series-title":"2-Aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as CDK inhibitors and their preparation","author":"Liu","year":"2016"},{"key":"10.1016\/j.apsb.2020.05.001_bib104","series-title":"Preparation of acetylcyclopentylmethylaminopyridopyrimidinone derivatives for use as CDK small-molecule inhibitors","author":"Liu","year":"2016"},{"key":"10.1016\/j.apsb.2020.05.001_bib105","series-title":"Preparation of fused heterocyclic compounds for treatment of cyclin-dependent kinase related diseases","author":"Wan","year":"2016"},{"key":"10.1016\/j.apsb.2020.05.001_bib106","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/jm401073p","article-title":"Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)","volume":"57","author":"Reddy","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib107","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40265-017-0742-0","article-title":"Ribociclib: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2020.05.001_bib108","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1080\/13543784.2017.1389896","article-title":"CDK4\/6 blockade in breast cancer: current experience and future perspectives","volume":"26","author":"Zardavas","year":"2017","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.apsb.2020.05.001_bib109","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000447284","article-title":"Clinical development of the CDK4\/6 inhibitors ribociclib and abemaciclib in breast cancer","volume":"11","author":"Barroso-Sousa","year":"2016","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.apsb.2020.05.001_bib110","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.05.001_bib111","series-title":"Preparation of pyrrolopyrimidine compounds as CDK inhibitors","author":"Besong","year":"2010"},{"key":"10.1016\/j.apsb.2020.05.001_bib112","series-title":"Preparation of pyrrolopyrimidine derivatives for use as CDK4\/6 inhibitors","author":"Brain","year":"2011"},{"key":"10.1016\/j.apsb.2020.05.001_bib113","series-title":"Preparation of CDK small molecule inhibitors","author":"Liu","year":"2016"},{"key":"10.1016\/j.apsb.2020.05.001_bib114","series-title":"Preparation of substituted pyrrolopyrimidine derivative as CDK inhibitor","author":"Wang","year":"2017"},{"key":"10.1016\/j.apsb.2020.05.001_bib115","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2020.05.001_bib116","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1080\/03007995.2017.1348344","article-title":"A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer","volume":"33","author":"Bilgin","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.apsb.2020.05.001_bib117","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.apsb.2020.05.001_bib118","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/1078155218770904","article-title":"Role of cyclin-dependent kinase 4\/6 inhibitors in the current and future eras of cancer treatment","volume":"25","author":"Parylo","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.apsb.2020.05.001_bib119","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","article-title":"CDK 4\/6 inhibitors in breast cancer: current controversies and future directions","volume":"21","author":"Spring","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.apsb.2020.05.001_bib120","doi-asserted-by":"crossref","first-page":"43678","DOI":"10.18632\/oncotarget.18435","article-title":"Biological specificity of CDK4\/6 inhibitors: dose response relationship, in\u00a0vivo signaling, and composite response signature","volume":"8","author":"Knudsen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2020.05.001_bib121","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.bmcl.2017.12.068","volume":"28","author":"Wang","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib122","series-title":"6-[2-(Pyridinyl-2-ylamino)pyrimidin-4-yl]imidazole compounds as CDK inhibitors and their preparation","author":"Liu","year":"2016"},{"key":"10.1016\/j.apsb.2020.05.001_bib123","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejmech.2018.02.022","article-title":"Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4\/6 inhibitors for cancer therapy","volume":"148","author":"Zha","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib124","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/1535-7163.MCT-15-0775","article-title":"Preclinical characterization of G1T28: a novel CDK4\/6 inhibitor for reduction of chemotherapy-induced myelosuppression","volume":"15","author":"Bisi","year":"2016","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3986","article-title":"Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion","volume":"9","author":"He","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.05.001_bib126","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jnci\/djs002","article-title":"Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy","volume":"104","author":"Roberts","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2020.05.001_bib127","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib128","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments anti-tumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2017","journal-title":"Canc Discov"},{"key":"10.1016\/j.apsb.2020.05.001_bib129","doi-asserted-by":"crossref","first-page":"42343","DOI":"10.18632\/oncotarget.16216","article-title":"Preclinical development of G1T38: a novel, potent and selective inhibitor of cyclin dependent kinases 4\/6 for use as an oral antineoplastic in patients with CDK4\/6 sensitive tumors","volume":"8","author":"Bisi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2020.05.001_bib130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/1541-7786.MCR-17-0028","article-title":"CDK4\/6 therapeutic intervention and viable alternative to taxanes in CRPC","volume":"15","author":"Stice","year":"2017","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib131","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1021\/jm500118j","article-title":"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3","volume":"57","author":"Li","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib132","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1535-7163.MCT-14-0388","article-title":"AMG 925 is a dual FLT3\/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia","volume":"14","author":"Li","year":"2015","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib133","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/1535-7163.MCT-13-0858","article-title":"Preclinical evaluation of AMG 925, a FLT3\/CDK4 dual kinase inhibitor for treating acute myeloid leukemia","volume":"13","author":"Keegan","year":"2014","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.apsb.2020.05.001_bib134","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/jm0309957","article-title":"2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity","volume":"47","author":"Wang","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib135","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.chembiol.2010.07.016","article-title":"Discovery and characterization of 2-anilino-4-(thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents","volume":"17","author":"Wang","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib136","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/jm301475f","article-title":"Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure\u2013activity relationship, and anticancer activities","volume":"56","author":"Shao","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib137","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acs.jmedchem.6b01670","article-title":"Highly potent, selective, and orally bioavailable 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation","volume":"60","author":"Tadesse","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib138","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4155\/fmc-2017-0076","article-title":"A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4\/6 inhibitors","volume":"9","author":"Tadesse","year":"2017","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib139","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/bph.13974","article-title":"Discovery and pharmacological characterization of a novel\u00a0series of highly selective inhibitors of cyclin-dependent kinases\u00a04 and 6 as anticancer agents","volume":"175","author":"Tadesse","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2020.05.001_bib140","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/ml200241a","article-title":"Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active CDK4\/6 inhibitors","volume":"3","author":"Cho","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib141","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1021\/jm100571n","article-title":"4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4\/6","volume":"53","author":"Cho","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib142","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bmcl.2008.11.090","article-title":"Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1\u2013CDK4: synthesis, biological evaluation, and structure\u2013activity relationships","volume":"19","author":"Horiuchi","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib143","doi-asserted-by":"crossref","first-page":"7850","DOI":"10.1016\/j.bmc.2009.10.039","article-title":"Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1\u2013CDK4: synthesis, biological evaluation, and structure\u2013activity relationships","volume":"17","author":"Horiuchi","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib144","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1248\/cpb.59.991","article-title":"Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based cyclin-dependent kinase 4 inhibitors: synthesis, biological evaluation and structure\u2013activity relationships","volume":"59","author":"Horiuchi","year":"2011","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.apsb.2020.05.001_bib145","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1016\/j.bmcl.2006.04.048","article-title":"Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9","volume":"16","author":"Shimamura","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib146","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1016\/S0960-894X(03)00792-3","article-title":"Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides","volume":"13","author":"Sanchez-Martinez","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib147","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.bmcl.2004.03.105","article-title":"1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors","volume":"14","author":"Al-Awar","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib148","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/S0960-894X(03)00461-X","article-title":"Novel, potent and selective cyclin D1\/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles","volume":"13","author":"Engler","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib149","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0960-894X(03)00133-1","article-title":"Synthesis of quinolinyl\/isoquinolinyl[a]pyrrolo[3,4-c]carbazoles as cyclin D1\/CDK4 inhibitors","volume":"13","author":"Zhu","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib150","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1016\/S0960-894X(03)00791-1","article-title":"Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1\u2013CDK4 inhibitors","volume":"13","author":"Sanchez-Martinez","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib151","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1021\/jm0103256","article-title":"Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design","volume":"44","author":"Honma","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib152","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/jm010326y","article-title":"A novel approach for the development of selective cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues","volume":"44","author":"Honma","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib153","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/acs.jafc.9b07103","article-title":"Asparanin A from Asparagus officinalis L. Induces G0\/G1 cell cycle arrest and apoptosis in human endometrial carcinoma ishikawa cells via mitochondrial and PI3K\/AKT signaling pathways","volume":"68","author":"Zhang","year":"2020","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib154","doi-asserted-by":"crossref","first-page":"104616","DOI":"10.1016\/j.phrs.2019.104616","article-title":"Icariside II inhibits tumorigenesis via inhibiting AKT\/Cyclin E\/CDK 2 pathway and activating mitochondria-dependent pathway","volume":"152","author":"Sun","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib155","doi-asserted-by":"crossref","first-page":"110013","DOI":"10.1016\/j.biopha.2020.110013","article-title":"Icariside II suppresses cervical cancer cell migration through JNK modulated matrix metalloproteinase-2\/9 inhibition in\u00a0vitro and in\u00a0vivo","volume":"125","author":"Sun","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2020.05.001_bib156","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1021\/acs.jafc.9b00324","article-title":"Licochalcone B extracted from Glycyrrhiza uralensis Fisch induces apoptotic effects in human hepatoma cell HepG2","volume":"67","author":"Wang","year":"2019","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib157","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1021\/acs.jafc.9b02759","article-title":"Mechanism of juglone-induced cell cycle arrest and apoptosis in ishikawa human endometrial cancer cells","volume":"67","author":"Zhang","year":"2019","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib158","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000484167","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors in breast cancer and potential biomarkers of response","volume":"12","author":"Guarducci","year":"2017","journal-title":"Breast Care"},{"key":"10.1016\/j.apsb.2020.05.001_bib159","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2020.05.001_bib160","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O'Leary","year":"2018","journal-title":"Canc Discov"},{"key":"10.1016\/j.apsb.2020.05.001_bib161","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1038\/onc.2010.154","article-title":"Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2020.05.001_bib162","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib163","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-16-2653","article-title":"Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer","volume":"77","author":"Jansen","year":"2017","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib164","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2020.05.001_bib165","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Canc Cell"},{"key":"10.1016\/j.apsb.2020.05.001_bib166","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1541-7786.MCR-17-0602","article-title":"Dual inhibition of CDK4 and CDK2 via targeting p27 tyrosine phosphorylation induces a potent and durable response in breast cancer cells","volume":"16","author":"Patel","year":"2018","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib167","series-title":"Preparation of heterocyclylaminopyrido[2,3-d]pyrimidin-7(8H)-one compounds as cyclin-dependent kinase inhibitors for treatment of proliferative diseases such as cancer","author":"Behenna","year":"2018"},{"key":"10.1016\/j.apsb.2020.05.001_bib168","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Canc Cell"},{"key":"10.1016\/j.apsb.2020.05.001_bib169","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.05.001_bib170","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/ijc.31220","article-title":"Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development\u00a0of BRAF inhibitor resistance","volume":"142","author":"Martin","year":"2018","journal-title":"Int J Canc"},{"key":"10.1016\/j.apsb.2020.05.001_bib171","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1038\/s41388-019-0708-7","article-title":"Combining CDK4\/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer","volume":"38","author":"Cao","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2020.05.001_bib172","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10549-018-05104-9","article-title":"Synergistic anti-cancer activity of CDK4\/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer","volume":"174","author":"Yamamoto","year":"2019","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.apsb.2020.05.001_bib173","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3109\/10428194.2015.1030641","article-title":"Phase 1\/2 study of cyclin-dependent kinase (CDK)4\/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"56","author":"Niesvizky","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.apsb.2020.05.001_bib174","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACs: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2020.05.001_bib175","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"PROTACs: induced protein degradation as a therapeutic strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib176","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.05.001_bib177","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.apsb.2020.05.001_bib178","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem Commun"},{"key":"10.1016\/j.apsb.2020.05.001_bib179","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.05.001_bib180","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1002\/anie.201901336","article-title":"Development of dual and selective degraders of cyclin-dependent kinases 4 and 6","volume":"58","author":"Jiang","year":"2019","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2020.05.001_bib181","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1039\/C9CC00163H","article-title":"PROTACs suppression of CDK4\/6, crucial kinases for cell cycle regulation in cancer","volume":"55","author":"Zhao","year":"2019","journal-title":"Chem Commun"},{"key":"10.1016\/j.apsb.2020.05.001_bib182","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","article-title":"Homolog-selective degradation as a strategy to probe the function of CDK6 in AML","volume":"26","author":"Brand","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2020.05.001_bib183","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.bmcl.2019.03.035","article-title":"Selective degradation of CDK6 by a palbociclib based PROTAC","volume":"29","author":"Rana","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.05.001_bib184","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders","volume":"62","author":"Su","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.05.001_bib185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Jr","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2020.05.001_bib186","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.apsb.2020.05.001_bib187","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discov"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520305839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520305839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:46:10Z","timestamp":1761929170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383520305839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":187,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2211383520305839"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.05.001","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective inhibition of CDK4\/6: A safe and effective strategy for developing anticancer drugs","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}